ProPhase Labs (NASDAQ:PRPH – Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect ProPhase Labs to post earnings of ($0.18) per share and revenue of $2.45 million for the quarter.
ProPhase Labs Trading Down 10.9 %
PRPH opened at $0.29 on Tuesday. The firm has a market capitalization of $12.34 million, a price-to-earnings ratio of -0.23 and a beta of -0.56. The company’s 50 day simple moving average is $0.36 and its two-hundred day simple moving average is $0.67. ProPhase Labs has a 1-year low of $0.22 and a 1-year high of $5.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on ProPhase Labs in a report on Tuesday, February 25th. They set a “sell” rating on the stock.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- Airline Stocks – Top Airline Stocks to Buy Now
- Chevron’s Fundamentals Shine Through Market Turmoil
- 5 discounted opportunities for dividend growth investors
- Qualcomm: Analyst Opinions Split, But Upside Potential Remains
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Monster Beverage Stock: Short Report Risks vs Upside Potential
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
